SCTX Stock Forecast & Price Target

Scribe Therapeutics is viewed favorably because STX-1150 has shown strong preclinical translatability, with >50% LDL-C lowering maintained for two years in NHPs, a >5x potency advantage in human hepatocytes, and no significant liver-safety signal, which supports the possibility of durable PCSK9 suppression at clinically practical doses. The company’s ELXR approach is differentiated because it silences PCSK9 without altering DNA, potentially widening the treatable ASCVD population versus permanent editing while addressing the real-world adherence problem that leaves many patients off goal. Financially, Scribe appears funded for the 1H27 readout and initial XE development, with roughly $180M pro forma cash, runway into 1H29, no long-term debt, and an implied EV near $360M that looks modest relative to the value of its pipeline and the Verve precedent.

Scribe Therapeutics is a preclinical-to-early clinical biotech with no product revenue, ongoing losses, and a first-in-human program that has only just entered the clinic, leaving its valuation vulnerable to execution risk rather than supported by human efficacy data. Its lead asset, STX-1150, relies on unproven epigenetic silencing, while the company’s other wholly owned LPA and APOC3 programs remain preclinical, so the pipeline still lacks the de-risking clinical evidence that supported Verve’s $549 million acquisition. Financially, management expects cash to fund operations into 1H29, but about $50.8 million of FY2026 burn and $81.9 million in FY2027 burn still imply continued dilution risk, and commercialization faces a crowded ASCVD market with uncertain reimbursement, safety, and adoption.